{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:05:01Z","timestamp":1784099101051,"version":"3.55.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2026.1881594","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:08Z","timestamp":1784095448000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Lidetian","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixing","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1820785","article-title":"Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities","volume":"17","author":"Xu","year":"2026","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/483531a","article-title":"Drug development: raise standards for preclinical cancer research","volume":"483","author":"Begley","year":"2012","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108749","article-title":"Exploring the landscape of post-translational modification in drug discovery","volume":"265","author":"Cao","year":"2025","journal-title":"Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \"beyond rule-of-five\" chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J Med Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov Today"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.822330","article-title":"Treatment of retinoblastoma: what is the latest and what is the future","volume":"12","author":"Schaiquevich","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104423","article-title":"Safety of intravitreal chemotherapy in the management of retinoblastoma: a systematic review of the literature","volume":"200","author":"Lavasidis","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1038\/s41598-025-34331-6","article-title":"B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma","volume":"16","author":"Sujjitjoon","year":"2026","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajo.2023.11.020","article-title":"Aqueous humor liquid biopsy as a companion diagnostic for retinoblastoma: implications for diagnosis, prognosis, and therapeutic options: five years of progress","volume":"263","author":"Berry","year":"2024","journal-title":"Am J Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1881594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:08Z","timestamp":1784095448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1881594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1881594"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1881594","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1881594"}}